Stockscreener 앱 받기
0.5825
11.34%
-0.0745
시간 외 거래:
.56
-0.0225
-3.86%
전일 마감가:
$0.657
열려 있는:
$0.64
하루 거래량:
367.09K
Relative Volume:
0.20
시가총액:
$3.72M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-14.71%
1개월 성능:
-6.05%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.5713
$0.6439
1주일 범위
$0.5713
$0.7343
52주 변동 폭
$0.5713
$1.41
Decoy Therapeutics Inc Stock (DCOY) Company Profile
명칭
Decoy Therapeutics Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
0.5825 | 4.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 개시 | Ladenburg Thalmann | Buy |
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc 주식(DCOY)의 최신 뉴스
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split - Finviz
Decoy Therapeutics Announces Reverse Stock Split to Maintain Listing - TipRanks
Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com India
Biotech Decoy Therapeutics shrinks shares 12-to-1 to meet Nasdaq $1 rule - Stock Titan
SLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Decoy Therapeutics (DCOY) Stock Analysis Report | Financials & Insights - Benzinga España
Decoy Therapeutics shareholders approve reverse stock split and equity plan - Investing.com Nigeria
Decoy Therapeutics shareholders approve reverse stock split and equity plan By Investing.com - Investing.com India
Decoy Therapeutics Shareholders Approve Plan and Reverse Split - TipRanks
DCOY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
DCOY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Decoy Therapeutics Joins Webull Corporate Connect Service Platfo - GuruFocus
Decoy Therapeutics Joins Webull Corporate Connect Service Platform - marketscreener.com
Follow Decoy Therapeutics updates on Webull app now - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Finviz
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Gates Foundation backs Decoy's push for rapid, low-cost antivirals - Stock Titan
Decoy Therapeutics (DCOY) Stock Price, News & Analysis - MarketBeat
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Decoy Therapeutics (DCOY) Receives "Buy" Rating from Ladenburg T - GuruFocus
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
DCOY Stock Price, News & Analysis - Stock Titan
Decoy Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
DCOYDECOY THERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics rises as Gates Foundation backs antiviral drug access - TradingView
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
What is the current Price Target and Forecast for Decoy Therapeutics Inc (DCOY) - Zacks Investment Research
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
symbol__ Stock Quote Price and Forecast - CNN
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - The Globe and Mail
Salarius Pharmaceuticals changes name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Salarius Pharmaceuticals Changes Corporate Name to Decoy - GlobeNewswire
Decoy Therapeutics Inc (DCOY) 재무 분석
Decoy Therapeutics Inc (DCOY)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):